Physician profile
David Pai
NPI 1023190808
$22,247.64
in general payments reported to CMS, 2019-2025
12 companies · $424 in 2025
The $424 reported for 2025 was more than what 76% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $210 · 2020: $22.35 · 2021: $187 · 2022: $18K · 2023: $2,467 · 2024: $591 · 2025: $424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $2,000 · Food and Beverage: $1,433 · Education: $49.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $2,000.00 |
| Food and Beverage | $1,432.88 |
| Education | $49.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $18,360.48 | 2019-2023 | Veltassa |
| Fresenius USA Marketing, INC. | $2,132.41 | 2023 | Korsuva, Velphoro |
| Novartis Pharmaceuticals Corporation | $487.76 | 2024-2025 | |
| Amgen INC. | $260.76 | 2022-2025 | Tavneos, Krystexxa |
| Travere Therapeutics, INC. | $260.42 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $238.29 | 2023-2024 | |
| Aurinia Pharma U.S., INC. | $195.90 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $181.85 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.84 | 2024-2025 | |
| Glaxosmithkline, LLC. | $38.48 | 2022-2025 | Benlysta |
| Ardelyx, INC. | $31.10 | 2024 | Ibsrela |
| Astrazeneca Pharmaceuticals Lp | $20.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Pai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.